Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMIT
NL-OMON60531Phase 3Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of warfarin (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Primary composite efficacy and safety endpoint. Started Nov 2022; status: recruiting.
02
Drugs
warfarin
Beyond the preview
Go deeper on NL-OMON60531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60531.